Lymphoma

CURE spoke with an expert on the importance of classifying T-cell lymphomas and what is next in this field.

Patients with activated B-cell-like lymphoma may not respond to standard treatment, so new options are being explored.

Updated trial data shows that Opdivo had a high objective response rate for a cohort of patients with classical Hodgkin Lymphoma.

By mitigating some of the financial burdens, The Leukemia & Lymphoma Society helps patients better stick to treatment regimens.

By taking the brakes off immune response, immunotherapy empowers the body to fight resistant or recurrent classical Hodgkin lymphoma.

There’s an enormous — and growing — menu of treatments for B cell lymphomas.

Adcetris met its primary endpoint in a phase 3 trial for patients with T-cell lymphoma.

A tango program for cancer survivors is showing to have benefits far beyond developing graceful dance moves.

Data from the KEYNOTE-087 study showed overall response rates of about 70 to 80 percent in three separate groups of relapsed/refractory Hodgkin lymphoma patients.

A recent study showed that for young women who were treated for cancer, the issue of fertility is not adequately addressed.

The FDA approved Opdivo (nivolumab) for classical Hodgkin lymphoma (cHL).

Men whose partners are diagnosed with cancer may need to learn new strategies to become effective caregivers.

Only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition scan.

Paring down treatment for Hodgkin lymphoma may reduce the risk of long-term side effects. Minimizing without hurting cure rates is the challenge.

Patients with cancer aren't the only ones who need a little levity in their lives.

Shannon Kerr isn't shy about proclaiming her status as a cancer survivor. At the 2016 Battlefrog Fiesta Bowl in Phoenix, Kerr was joined by a stadium full of fans in drawing attention to the disease and the toll it can take.

Only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition (MUGA) scan.

I couldn't figure out how to fit in before this post. I read the blogs in the CURE community of contributors and I read the articles on the CURE home page — nothing.

If you have a family member who is sick or terminally ill, my advice to approach a holiday is to remain festive, even if the person you want to celebrate does not appear inclined to join in too many festivities. The holiday may become one you will never forget.

Most cancer survivors are familiar with Psalm 23 and the feeling of walking through the valley of the shadow. We also need to remember that there's another side to the valley, where the light shines brightly.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

I don't sign the hospitality guest book. I'm a ghost floating through the corridors. I don't want to make an impact here; don't want to call Roswell Park Cancer Institute home. But when a stranger offers comfort, I'm filled with hope.

By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.

Two transplants, three mini triathons. Running the race for myself and others shows how lessons learned in the hospital translate to victory on the outside.

Questions persist regarding mechanisms of PD-L1 overexpression in lymphoid malignancies, patient selection, biomarkers to guide therapy and predict response, and identification of agents to use in combination with PD-1/PD-L1 inhibitors.

Two types of effective treatments for non-Hodgkin lymphoma are cell signaling inhibitors and monoclonal antibodies.

Returning to the mechanics of transplant, Kevin gives some details of the six-month milestone, but is unable to refrain from a bit of hopeful philosophy.

Fred R. Hirsch, from the University of Colorado and IASLC, discusses some of the unique challenges he faced as a patient.